Genetic pathways in the evolution of breast ductal carcinoma in situ

被引:56
作者
Farabegoli, F
Champeme, MH
Bieche, I
Santini, D
Ceccarelli, C
Derenzini, M
Lidereau, R
机构
[1] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy
[2] Ctr Rene Huguenin, INSERM E0017, St Cloud, France
[3] Univ Bologna, Inst Anat & Histol Pathol, I-40126 Bologna, Italy
关键词
loss of heterozygosity (LOH); ductal carcinoma in situ (DCIS); genetic alterations;
D O I
10.1002/path.1048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The patterns of allelic loss in 28 cases of pure ductal carcinoma in situ (DCIS) and 25 cases of DCIS associated with invasive ductal carcinoma (IDC) were compared, in order to define whether pure DCIS represented an earlier stage than DCIS associated with IDC in the progression of breast carcinoma. To this aim, the polymerase chain reaction (PCR) was performed on microdissected normal and neoplastic breast tissue, formalin-fixed and paraffin-embedded. Fifteen microsatellite markers were examined, on chromosomes 1p, 3p, 7q, 11q, 12p, 13q, 16q and 17q, mostly focused on regions altered in breast cancer. Loss of heterozygosity (LOH) was greater in pure than in the DCIS component associated with Ill for I I out of 15 markers. The difference was statistically significant for D13S260 and D17S800 (p=0.008 and p=0.01, respectively). DCIS associated with IDC showed a lesser degree of alteration than the synchronous IDC component for ten out of 15 markers. In contrast, LOH at D11S1816 and D16S318 was lower in pure DCIS than in DCIS associated with IDC and even greater in the IDC component. These results confirm that DCIS is a possible but not an obligate precursor of invasive breast cancer and suggest that pure DCIS and DCIS associated with Ill may be genetically distinct. The evolution from DCIS to Ill may follow multiple pathways and not a linear model. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:280 / 286
页数:7
相关论文
共 31 条
[1]   Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer [J].
Beckmann, MW ;
Picard, F ;
An, HX ;
vanRoeyen, CRC ;
Dominik, SI ;
Mosny, DS ;
Schnurch, HG ;
Bender, HG ;
Niederacher, D .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1220-1226
[2]   GENETIC ALTERATIONS IN BREAST-CANCER [J].
BIECHE, I ;
LIDEREAU, R .
GENES CHROMOSOMES & CANCER, 1995, 14 (04) :227-251
[3]  
Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO
[4]  
2-L
[5]   Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas [J].
Chappell, SA ;
Walsh, T ;
Walker, RA ;
Shaw, JA .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1324-1329
[6]  
Chen TP, 1996, CANCER RES, V56, P5605
[7]  
Driouch K, 1998, CANCER RES, V58, P2081
[8]   Mapping lass of heterozygosity at chromosome 13q:: Loss at 13q12-q13 is associated with breast tumour progression and poor prognosis [J].
Eiriksdottir, G ;
Johannesdottir, G ;
Ingvarsson, S ;
Björnsdottir, IB ;
Jonasson, JG ;
Agnarsson, BA ;
Hallgrimsson, J ;
Gudmundsson, J ;
Egilsson, V ;
Sigurdsson, H ;
Barkardottir, RB .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (13) :2076-2081
[9]  
Fujii H, 1996, CANCER RES, V56, P5260
[10]   Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness [J].
Glöckner, S ;
Lehmann, U ;
Wilke, N ;
Kleeberger, R ;
Länger, F ;
Kreipe, H .
LABORATORY INVESTIGATION, 2001, 81 (04) :565-571